title: [Two-phase responses of acid expulsion triggered by alpha-1a adrenoceptor in CHO cell].
abstract: Using microphysiometer, we have investigated acid expulsion from CHO cells expressing human alpha-1a adrenoceptor. Time course of extracellular acidification rate after noradrenaline stimulation had two phases; one with a peak within 10 s reached several folds of base rate, and another increased gradually to two folds of base rate and reached plateau around two min. Both phases showed concentration-dependent increase of acidification rates in response to noradrenaline but had distinct pEC50 values; 6.0 for rapid phase and 6.6 for late phase. Amiloride and its analogs inhibited both phases entirely, suggesting that Na/H exchanger mainly mediated these acid expulsion responses. Elimination of Ca by BAPTA/EGTA treatment resulted in extensive reductions of the rapid phase response but small decrease of the late phase response. Several Ca channel blockers, Ni and LOE908 also suppressed the rapid phase while nifedipine, verapamil, SKF96365 and omega-conotoxin GIVA did not. Repeated stimulation with noradrenaline enhanced inhibitory effect of blockers. These results indicate that Ca is one of the elements in the rapid phase but not in the late phase of acid expulsion from CHO cells in response to alpha-1 adrenoceptor stimulation and suggest that Ca from both intracellular storage and some type of Ca channel dominantly participates in the rapid phase.
authors.affiliation: Department of Pharmacology, School of Medicine, Fukui Medical University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Taniguchi
authors.forename: R
authors.initials: R
authors.lastname: Inagaki
authors.forename: R
authors.initials: R
authors.lastname: Takauji
authors.forename: F
authors.initials: F
authors.lastname: Suzuki
authors.forename: I
authors.initials: I
authors.lastname: Muramatsu
mesh_terms: D000081:Acetamides / Q000494:pharmacology; D000143:Acids; D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D016466:CHO Cells; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020916:Conotoxins / Q000494:pharmacology; D006224:Cricetinae; D004533:Egtazic Acid / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D009543:Nifedipine / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D014700:Verapamil / Q000494:pharmacology
chemical_list: D000081:Acetamides; D000143:Acids; D002121:Calcium Channel Blockers; D020916:Conotoxins; D007093:Imidazoles; D007546:Isoquinolines; D011942:Receptors, Adrenergic, alpha; C081356:LOE 908; D004533:Egtazic Acid; D000584:Amiloride; D014700:Verapamil; C063159:1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole; D009543:Nifedipine; D009638:Norepinephrine